Oncol-话题@MedSci

#Oncol#

2384篇内容 | 2473人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1866318, encodeId=c2151866318b1, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Front Oncol：一线化疗的基础上联合PD-1抑制剂可改善晚期胆道癌患者的预后, objectType=article, longId=219199, objectId=9d6e219199ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9d6e219199ce, replyNumber=0, likeNumber=69, createdTime=2022-08-12, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9d6e219199ce, moduleTitle=Front Oncol：一线化疗的基础上联合PD-1抑制剂可改善晚期胆道癌患者的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9d6e219199ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866349, encodeId=33f41866349ca, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=JAMA Oncology：全反式视黄酸联合三氧化二砷，对儿童白血病疗效显著, objectType=article, longId=220348, objectId=fcbd22034828, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fcbd22034828, replyNumber=0, likeNumber=91, createdTime=2022-05-20, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fcbd22034828, moduleTitle=JAMA Oncology：全反式视黄酸联合三氧化二砷，对儿童白血病疗效显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fcbd22034828)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866277, encodeId=066018662e706, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Front Oncol：可切除NSCLC患者术前化疗联合免疫治疗是安全可行的, objectType=article, longId=218270, objectId=6a462182e009, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6a462182e009, replyNumber=0, likeNumber=70, createdTime=2022-03-07, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6a462182e009, moduleTitle=Front Oncol：可切除NSCLC患者术前化疗联合免疫治疗是安全可行的, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6a462182e009)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866092, encodeId=04b6186609244, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Hematol Oncol：术后循环肿瘤DNA（ctDNA）可用于II/III其结直肠癌患者复发风险预测指标, objectType=article, longId=211566, objectId=9376211566f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9376211566f4, replyNumber=0, likeNumber=72, createdTime=2021-08-13, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9376211566f4, moduleTitle=J Hematol Oncol：术后循环肿瘤DNA（ctDNA）可用于II/III其结直肠癌患者复发风险预测指标, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9376211566f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866518, encodeId=3ae918665183e, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Target Oncol:真实世界评估阿比特龙+泼尼松或泼尼松龙(AAP)一线或二线治疗转移性去势抵抗前列腺癌(mCRPC)的疗效和安全性, objectType=article, longId=299289, objectId=97bb29928916, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=97bb29928916, replyNumber=0, likeNumber=60, createdTime=2022-10-26, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=97bb29928916, moduleTitle=Target Oncol:真实世界评估阿比特龙+泼尼松或泼尼松龙(AAP)一线或二线治疗转移性去势抵抗前列腺癌(mCRPC)的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=97bb29928916)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866505, encodeId=c2dc186650505, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Lancet Oncol：纳武单抗联合奥沙利铂化疗一线治疗晚期或复发性胃或胃食管交界癌, objectType=article, longId=295669, objectId=d4cf2956690e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d4cf2956690e, replyNumber=0, likeNumber=67, createdTime=2022-11-09, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d4cf2956690e, moduleTitle=Lancet Oncol：纳武单抗联合奥沙利铂化疗一线治疗晚期或复发性胃或胃食管交界癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d4cf2956690e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866460, encodeId=377b1866460dc, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Front Oncol：TACE联合ICIs+TKIs治疗不可切除肝细胞癌的疗效, objectType=article, longId=294112, objectId=1b49294112ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1b49294112ae, replyNumber=0, likeNumber=69, createdTime=2022-04-13, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1b49294112ae, moduleTitle=Front Oncol：TACE联合ICIs+TKIs治疗不可切除肝细胞癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1b49294112ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866244, encodeId=a4a1186624424, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=JAMA Oncol：过去40年接受同种异体血液或骨髓移植的患者的死亡率和寿命变化趋势, objectType=article, longId=217542, objectId=d22c21e5428b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d22c21e5428b, replyNumber=0, likeNumber=88, createdTime=2022-05-25, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d22c21e5428b, moduleTitle=JAMA Oncol：过去40年接受同种异体血液或骨髓移植的患者的死亡率和寿命变化趋势, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d22c21e5428b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866512, encodeId=277f186651292, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=期刊推荐：Journal of Hematology & Oncology, objectType=article, longId=295756, objectId=c07a295e56e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c07a295e56e4, replyNumber=0, likeNumber=17, createdTime=2022-10-26, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c07a295e56e4, moduleTitle=期刊推荐：Journal of Hematology & Oncology, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c07a295e56e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866341, encodeId=1ac41866341ac, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Thorac Oncol：ADAURA研究：IB-IIIA期EGFR突变阳性NSCLC切除术后使用奥希替尼辅助治疗改善患者DFS，无论是否接受辅助化疗, objectType=article, longId=220083, objectId=ae6a2200837d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ae6a2200837d, replyNumber=0, likeNumber=60, createdTime=2022-05-29, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ae6a2200837d, moduleTitle=J Thorac Oncol：ADAURA研究：IB-IIIA期EGFR突变阳性NSCLC切除术后使用奥希替尼辅助治疗改善患者DFS，无论是否接受辅助化疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ae6a2200837d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866457, encodeId=2b30186645ee3, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：Ibrutinib（伊布替尼）联合Rituximab（利妥昔单抗）治疗惰性套细胞淋巴瘤(IMCL-2015)的疗效, objectType=article, longId=294056, objectId=900f294056ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=900f294056ec, replyNumber=0, likeNumber=72, createdTime=2022-11-25, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=900f294056ec, moduleTitle=J Clin Oncol：Ibrutinib（伊布替尼）联合Rituximab（利妥昔单抗）治疗惰性套细胞淋巴瘤(IMCL-2015)的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=900f294056ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866310, encodeId=9c9c1866310d2, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Front Oncol：真实世界中CA199的监测模式跟转移性胰腺导管腺癌(PDAC)预后的关系, objectType=article, longId=219136, objectId=f1372191363a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f1372191363a, replyNumber=0, likeNumber=64, createdTime=2021-10-30, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f1372191363a, moduleTitle=Front Oncol：真实世界中CA199的监测模式跟转移性胰腺导管腺癌(PDAC)预后的关系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f1372191363a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866377, encodeId=469418663e79b, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Front Oncol：基于SEER数据库比较前列腺癌根治术（PR）和放疗（RT）治疗转移性前列腺癌的生存结果, objectType=article, longId=221181, objectId=8b0d221181c4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8b0d221181c4, replyNumber=0, likeNumber=60, createdTime=2022-05-23, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8b0d221181c4, moduleTitle=Front Oncol：基于SEER数据库比较前列腺癌根治术（PR）和放疗（RT）治疗转移性前列腺癌的生存结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8b0d221181c4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866372, encodeId=345418663e2e7, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Front Oncol：SMART+顺铂（CDDP）/S1治疗老年食管鳞状细胞癌（ESCC）患者的疗效和安全性, objectType=article, longId=221107, objectId=ae7022110e3c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ae7022110e3c, replyNumber=0, likeNumber=59, createdTime=2022-09-14, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ae7022110e3c, moduleTitle=Front Oncol：SMART+顺铂（CDDP）/S1治疗老年食管鳞状细胞癌（ESCC）患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ae7022110e3c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866191, encodeId=3e7e18661917d, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=JAMA Oncol：二甲双胍联合同步放化疗治疗局部晚期非小细胞肺癌（NRG-LU001研究，附点评）, objectType=article, longId=215628, objectId=4ff021562880, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4ff021562880, replyNumber=0, likeNumber=77, createdTime=2022-03-23, rootId=0, userName=docwu2019, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4ff021562880, moduleTitle=JAMA Oncol：二甲双胍联合同步放化疗治疗局部晚期非小细胞肺癌（NRG-LU001研究，附点评）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4ff021562880)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866575, encodeId=f66218665e5ca, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：B细胞成熟抗原和CD19嵌合抗原受体T细胞联合治疗多发性骨髓瘤的长期疗效, objectType=article, longId=301786, objectId=fb92301e86b3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fb92301e86b3, replyNumber=0, likeNumber=81, createdTime=2022-10-03, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fb92301e86b3, moduleTitle=J Clin Oncol：B细胞成熟抗原和CD19嵌合抗原受体T细胞联合治疗多发性骨髓瘤的长期疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fb92301e86b3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866549, encodeId=1172186654909, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Lancet Oncol：鲁卡帕利可作为BRCA1/2突变的复发性卵巢癌化疗的替代选择, objectType=article, longId=300992, objectId=cea030099207, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cea030099207, replyNumber=0, likeNumber=0, createdTime=2022-09-30, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cea030099207, moduleTitle=Lancet Oncol：鲁卡帕利可作为BRCA1/2突变的复发性卵巢癌化疗的替代选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cea030099207)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866204, encodeId=d29e1866204c0, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：高危型乳腺导管原位癌肿瘤切除术后是否需要放疗？, objectType=article, longId=216121, objectId=ba50216121bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ba50216121bc, replyNumber=0, likeNumber=94, createdTime=2022-06-01, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ba50216121bc, moduleTitle=J Clin Oncol：高危型乳腺导管原位癌肿瘤切除术后是否需要放疗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ba50216121bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866528, encodeId=1dcc186652814, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：二次细胞减灭术对铂敏感的复发性卵巢癌患者生存期的影响, objectType=article, longId=299554, objectId=e3252995544f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e3252995544f, replyNumber=0, likeNumber=76, createdTime=2023-02-04, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e3252995544f, moduleTitle=J Clin Oncol：二次细胞减灭术对铂敏感的复发性卵巢癌患者生存期的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e3252995544f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866083, encodeId=ee3c18660839c, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Thorac Oncol：德瓦鲁单抗（durvalumab）维持治疗在EGFR和HER2突变不可切除III期NSCLC患者的作用, objectType=article, longId=211341, objectId=0e6621134127, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0e6621134127, replyNumber=0, likeNumber=53, createdTime=2022-01-31, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0e6621134127, moduleTitle=J Thorac Oncol：德瓦鲁单抗（durvalumab）维持治疗在EGFR和HER2突变不可切除III期NSCLC患者的作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0e6621134127)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Oncol

2020-05-29

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Front Oncol：一线化疗的基础上联合PD-1抑制剂可改善晚期胆道癌患者的预后

2022-08-12

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

JAMA Oncology：全反式视黄酸联合三氧化二砷，对儿童白血病疗效显著

2022-05-20

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Front Oncol：可切除NSCLC患者术前化疗联合免疫治疗是安全可行的

2022-03-07

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Hematol Oncol：术后循环肿瘤DNA（ctDNA）可用于II/III其结直肠癌患者复发风险预测指标

2021-08-13

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Target Oncol:真实世界评估阿比特龙+泼尼松或泼尼松龙(AAP)一线或二线治疗转移性去势抵抗前列腺癌(mCRPC)的疗效和安全性

2022-10-26

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Lancet Oncol：纳武单抗联合奥沙利铂化疗一线治疗晚期或复发性胃或胃食管交界癌

2022-11-09

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Front Oncol：TACE联合ICIs+TKIs治疗不可切除肝细胞癌的疗效

2022-04-13

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

JAMA Oncol：过去40年接受同种异体血液或骨髓移植的患者的死亡率和寿命变化趋势

2022-05-25

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

期刊推荐：Journal of Hematology & Oncology

2022-10-26

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Thorac Oncol：ADAURA研究：IB-IIIA期EGFR突变阳性NSCLC切除术后使用奥希替尼辅助治疗改善患者DFS，无论是否接受辅助化疗

2022-05-29

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：Ibrutinib（伊布替尼）联合Rituximab（利妥昔单抗）治疗惰性套细胞淋巴瘤(IMCL-2015)的疗效

2022-11-25

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Front Oncol：真实世界中CA199的监测模式跟转移性胰腺导管腺癌(PDAC)预后的关系

2021-10-30

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Front Oncol：基于SEER数据库比较前列腺癌根治术（PR）和放疗（RT）治疗转移性前列腺癌的生存结果

2022-05-23

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Front Oncol：SMART+顺铂（CDDP）/S1治疗老年食管鳞状细胞癌（ESCC）患者的疗效和安全性

2022-09-14

docwu2019 (审核中...)

前往app查看评论内容

#Oncol#

JAMA Oncol：二甲双胍联合同步放化疗治疗局部晚期非小细胞肺癌（NRG-LU001研究，附点评）

2022-03-23

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：B细胞成熟抗原和CD19嵌合抗原受体T细胞联合治疗多发性骨髓瘤的长期疗效

2022-10-03

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Lancet Oncol：鲁卡帕利可作为BRCA1/2突变的复发性卵巢癌化疗的替代选择

2022-09-30

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：高危型乳腺导管原位癌肿瘤切除术后是否需要放疗？

2022-06-01

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：二次细胞减灭术对铂敏感的复发性卵巢癌患者生存期的影响

2023-02-04

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Thorac Oncol：德瓦鲁单抗（durvalumab）维持治疗在EGFR和HER2突变不可切除III期NSCLC患者的作用

2022-01-31

科室
- - 订阅+
  - 更多科室
工具
服务